| Autor: |
Lugogo, Njira, Gilbert, Ileen, Pollack, Michael, Gandhi, Hitesh, Tkacz, Joseph, Lanz, Miguel J |
| Předmět: |
|
| Zdroj: |
Journal of Asthma & Allergy; May2023, Vol. 16, p579-584, 6p |
| Abstrakt: |
Among patients receiving any post-index SCS, annual estimated total mean mg of ICS exposure were 6-21-fold lower (medium/high-dose ICS and SABA-only groups, respectively) than observed annual post-index mean mg of SCS exposure. These estimations should serve to assuage concerns at a real-world population level regarding the risk of excessive ICS exposure from the budesonide component of an albuterol-budesonide fixed-dose combination rescue therapy. For each maintenance therapy group, the mean observed post-index ICS exposure was below the respective maximum FDA-approved levels, ranging from 24% (high-dose ICS-LABA) to 52% (low-dose ICS) of FDA-approved maximum daily doses. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
